Long non-coding RNA p53 upregulated regulator of p53 levels (PURPL) promotes the development of gastric cancer

Zhonghua Cheng*, Jing Hong*, Nan Tang, Fenghua Liu, Shuo Gu, and Zhen Feng

Department of Gastroenterology, The Central Hospital of Xuhui District, Xuhui Hospital, Zhongshan Hospital Affiliated to Fudan University, Shanghai, China

ABSTRACT

Gastric cancer (GC), one of the most prevalent malignancies across the world, has an increasing incidence rate. Long non-coding RNA (IncRNA) PURPL (also referred to as LINC01021) has been demonstrated to influence malignant GC behaviors and partake in other cancers. Notwithstanding, reports pertaining to the underlying mechanism of PURPL in GC haven’t been rarely seen. Presently, in-vivo and ex-vivo experiments were implemented to examine the PURPL-miR-137-ZBTB7A-P13K-AKT-NF-κB regulatory axis in GC. Our statistic analysis revealed that PURPL presented a high expression in GC tissues and cell lines. PURPL overexpression remarkably exacerbated colony formation, migration, and invasion and repressed apoptosis in GC cells (AGS and MNK-45). In-vivo experiments also corroborated that cell growth was boosted by PURPL up-regulation. Mechanistic investigations verified that PURPL interacted with miR-137 and lowered its profile in GC cell lines. miR-137 overexpression or ZBTB7A knockdown upended the oncogenic function mediated by PURPL. PURPL initiated the P13K/AKT/NF-κB pathway. P13K and NF-κB inhibition impaired the promoting impact on GC cells elicited by PURPL overexpression and contributed to PURPL down-regulation. These findings disclosed that PURPL serves as an oncogene in the context of GC via miR-137-ZBTB7A-P13K-AKT-NF-κB axis modulation.

Introduction

Gastric cancer (GC) is known as a malignancy stemming from gastric epithelial cells. It is a leading contributor to cancer-related death worldwide [1,2]. High-risk factors for gastric cancer incorporate helicobacter pylori infection, obesity, dietary habits, and family history [3]. The early phase of gastric cancer is characterized by opaque symptoms and low diagnostic rates, while the advanced phase usually features metastasis, poor prognosis, and low five-year survival rates [4,5]. The primary approaches to advanced gastric cancer treatment encompass immunotherapy, targeted molecular therapy, and adjuvant chemoradiotherapy [6]. Hence, a probe into the molecular mechanism of gastric cancer development helps discover novel targets for diagnosis and therapy.

Long non-coding RNAs (IncRNAs), non-coding RNA molecules consisting of over 200 nucleotides, are associated with a large number of gene expressions and functional regulation in cells [7–9]. Many IncRNAs have been regarded as underlying molecular markers of tumors, characterized by aberrant expressions in tumors like lung cancer, hepatocellular carcinoma, colon cancer, and gastric cancer, and regulatory impact on tumor cell proliferation, migration, and invasion [10–12]. IncRNA PURPL, another member of the IncRNA family, is also termed LINC01021. It has been discovered to modulate P53 to boost liver cancer cell proliferation and differentiation [13]. Another study showed that IncRNA PURPL and miR-338-3p dysregulation can be adopted as the biomarkers of epithelial ovarian cancer prognosis [14]. Nevertheless, the function of IncRNA PURPL in gastric cancer progression has not been elucidated so far.

microRNAs (miRNAs), small endogenous non-coding RNAs comprised of approximately 22 nucleotides, curb messenger RNA (mRNA)
translation or initiate mRNA degradation to regulate post-transcriptional gene expressions \[15,16\]. The aberrant profiles of umpteen miRNAs have been uncovered to partake in GC tumor progression and regulate GC cells’ proliferation, differentiation, migration, apoptosis and other cell cycles \[17–19\]. For instance, miR-96-5p exhibits a high expression in the plasma of GC patients and GC cells, and miR-96-5p facilitates GC cell proliferation \[20\]. miR-339-5p displays a low expression in GC tissues plays an anti-tumor role by restraining the proliferation and migration of GC cells \[21\]. miR-137 fights proliferation and migration in pituitary adenoma and colorectal cancer, suggesting its tumor suppressor role in tumor progression \[22,23\]. Nonetheless, the function of IncRNA PURPL/miR-137 axis in GC hasn’t come to light yet.

GC occurrence and development pertain to the sophisticated regulatory network among IncRNAs, miRNAs, and mRNAs \[24,25\]. For instance, miR-5003 is targeted by IncRNA RP11-789C1.1. RP11-789C1.1 expression down-regulation can heighten the profile of miR-5003, abate that of E-cadherin, and elicit epithelial mesenchymal transformation (EMT), bolstering GC cell proliferation and migration \[26\]. Zinc finger and BTB domain containing 7A (ZBTB7A), a member of the POK family, possesses a POZ domain at the N terminal and a Krüppel-like zinc finger domain at the C terminal. It has been demonstrated to function as a proto-oncogene to elicit tumor transformation and progression \[27\]. Nonetheless, a deeper probe into the upstream regulatory mechanism of ZBTB7A in the cancer is warranted.

In this study, attempts were made to explore IncRNA PURPL’s regulation on miR-137 and ZBTB7A molecules as well as its impact on the development of gastric cancer. We confirmed enhanced PURPL and ZBTB7A, but reduced miR-137 level in GC tissues and cells. PURPL overexpression promoted GC development, as well as upregulated ZBTB7A and PI3K-AKT-nuclear factor-kappaB (NF-κB) signaling pathway expression. Thus, we guessed there is a IncRNA PURPL-miR-137-ZBTB7A and PI3K-AKT-NF-κB regulatory axis contributing to GC development. Our study reveals that IncRNA PURPL is an underlying target for gastric cancer treatment, also an essential indicator for projecting its prognosis.

**Methods and materials**

**Collection of tissue specimens**

From October 2015 to October 2016, cancer tissues were harvested from 21 patients diagnosed with gastric cancer. They had never received chemotherapy or radiotherapy before they underwent surgery in Xuhui hospital of Zhongshan Hospital Affiliated to Fudan University. The characteristics of tissues were independently confirmed by three pathologists. Once the tissues were resected from the patients, they were frozen at −80°C. All patients participating in the study had signed the informed consent. The protocols concerning the usage of patient samples had been authorized by the Medical Ethics Committee of Xuhui hospital of Zhongshan Hospital Affiliated to Fudan University (Approved number: XHH-2020-0122) and were implemented in keeping with the World Medical Association Declaration of Helsinki.

**Cell culture**

The normal human gastric epithelial cell line GES-1 and gastric cell lines AGS, GC9811-P, MKN-45, and HSC-39, ordered from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China), were placed in a culture solution supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific, MA, USA), 1% penicillin/streptomycin (Invitrogen, CA, USA), and RPMI 1640 (Thermo Fisher Scientific, MA, USA) and cultured at 37°C with 5% CO₂. The solution was refreshed every three days, and 0.25% trypsin (Thermo Fisher HyClone, Utah, USA) was taken for digestion and passage. Cells in the logarithmic growth stage were harvested for subsequent procedures.

**Cell transfection**

Cells from each group in the logarithmic growth phase were inoculated into 6-well plates with a density of 5 × 10⁶ cells/well. The cells were subjected to transfection after they achieved stable
growth. As per the instructions of FuGene *HD Transfection Reagent* (Roche, Shanghai, China), lncRNA PURPL overexpression plasmid (lncRNA PURPL) and its negative control (Vector), si-ZBTB7A and its negative control (si-NC) (purchased from GenePharma Co., Ltd., Shanghai, China), and miR-137 mimics (miR-137) and its negative control (miR-NC) (purchased from Guangzhou Ribobio Co., Ltd., Guangzhou, China) were transfected into AGS and MKN-45 cells, respectively. Each group’s cells were put in an incubator with 5% CO\textsubscript{2} at 37°C. Following 24-hour transfection, the original medium was substituted by a new one. Subsequent to 24 hours’ further culture, the cells were passed [28]. Real-time quantitative polymerase chain reaction (RT-qPCR) determined the profiles of lncRNA PURPL, ZBTB7A, and miR-137 with the aim to confirm the transfection efficiency.

**RT-qPCR**

Total RNA was extracted out of GES-1, AGS, GC9811-P, MKN-45, and HSC-39 cells employing TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The total RNA was transcribed into cDNA with the use of the PrimeScript™ Reagent kit (Invitrogen, Shanghai, China). Then real-time PCR was conducted with the assistance of SYBR GreenPCR reagent and ABI7500FAST Real-Time PCR (MedChemExpress, NJ, USA). The 2\textsuperscript{−ΔΔCT} approach was utilized to assess the relative profiles of lncRNA PURPL, miR-137, and ZBTB7A (U6 and GAPDH were taken as internal references) [29]. Primer sequences are detailed below:

**Colony formation assay**

AGS and MKN-45 cells in each group in the logarithmic growth phase were harvested and seeded onto 6-mm dishes incorporating an RPMI 1640 medium. Each dish accommodated 1000 cells. The cells were conflated and cultured in an incubator. Twenty-four hours later, the medium was displaced by a complete medium. With the medium renewed every three to four days, the whole culture process lasted for 12 days. Following PBS washing, 4% paraformaldehyde was utilized for 10 minutes’ fixation, and 5% crystal violet staining was implemented for 10 minutes. After photos were captured, Image-ProPlus was introduced to calculate the number of cell clones formed in each dish [30]. Each experiment was duplicated three times, and measurement was implemented three times.

**Transwell assay**

The cell migration experiment: cells of each group in the logarithmic growth stage were administered to the upper Transwell chamber (8 µm pore size; Corning, NY, USA) (density: 2 × 10\textsuperscript{4} cells/well), with 600 µL of a culture solution incorporating 20% FBS given to the lower compartment. The cells were cultured at 37°C. After twelve hours, the upper cells were removed, and 4% paraformaldehyde was exploited to immobilize the lower cells. Staining with 0.1% crystal violet was carried out prior to photographing and counting the lower cells. In the cell invasion experiment: Matrigel (BD, Sanjose, USA) was utilized to coat the upper Transwell compartment prior to the addition of cells, and the other procedures were basically the same as those in the migration test. An inverted microscope (Olympus, Tokyo, Japan) was harnessed to capture photos and monitor cell migration and invasion [31].

**Flow cytometry**

AGS and MKN-45 cells were dealt with 5 µg/ml cisplatin for 12 hours to induce apoptosis. After being flushed in PBS twice, cells from each group were resuspended in 150 µL Binding Buffer, with 10 µL of Annexin V-FITC and 5 µL of propidium iodide (PI) administered to the buffer. The cells were thoroughly mixed by gently swirling the centrifuge tube and incubated in the dark at 4°C for 15 minutes. FACS Calibur Flow Cytometer (BD Biosciences, Sanjose, CA, USA) was operated to track apoptosis in line with the instructions of the AnnexinV-FITC/PI Apoptosis Detection kit (Yasen Biotech Co., Ltd.) [32]

**Western blot**

AGS and MKN-45 cells (2 × 10\textsuperscript{6}) from the above groups were measured out and flushed in pre-cooled PBS 3 times. RIPA lysis buffer (Beyotime
Biotecnology, Shanghai, China) was applied to lyse the cells. As the supernatant was harvested, its protein concentration was ascertained through BCA. Next, 50 μg of total protein underwent 12% polyacrylamide gel electrophoresis and was electrically moved onto polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA, USA). After being sealed with 5% skimmed milk at room temperature for 2 hours and rinsed with 0.05% TBST 3 times, the membranes were incubated overnight at 4°C along with primary antibodies Anti-Bax (ab32503), Anti-Bcl2 (ab218123), Anti-Caspase3 (ab13847), Anti-PI3K (ab32089), Anti-p-PI3K (ab182651), Anti-AKT (ab8805), Anti-p-AKT (ab38449), Anti-NF-kB (ab16502), Anti-p-NF-kB (ab183559), and Anti-β-actin (ab115777). The antibodies were supplied by Abcam (MA, USA). Following TBST rinsing, the membranes were incubated along with the secondary antibody IgG (1:5,000, AB6721; Abcam) at room temperature for 1 hour. After they were flushed another three times, ECL reagent (Millipore, Billerica, MA, USA) was adopted for color development and imaging [31]. Image J was introduced to analyze the gray value of each protein.

**Dual luciferase activity assay**

The ENCORI database (http://starbase.sysu.edu.cn/index.php) projected that miR-137 was potentially targeted by IncRNA PURPL [33]. The wild- and mutant-type reporter plasmids of PURPL (PURPL-wt, PURPL-mut) were engineered. AGS cells were transfected together with miR-137 mimics and miR-NC. Forty-eight hours later, the luciferase activity was gauged as instructed. All the procedures were done in triplicate and duplicated three times.

**Fluorescence in situ hybridization (FISH)**

To verify the subcellular localization of PURPL in the tumor tissues and adjacent normal tissues, we implemented FISH. The paraffin-embedded sections of gastric cancer tissues and normal adjacent tissues were prepared. The slices were dewaxed, subjected to antigen repair, and flushed in 0.01 M PBST 3 times (5 min each). After being sealed with 5% BSA for an hour at room temperature, the sections were hybridized with a hybridization solution supplemented with PURPL probes (5 ng/ul, Sangon, Shanghai, China) for 15 hours at 4°C overnight. The nucleus was then dyed employing DAPI (Beyotime, Shanghai, China) for 5 min at room temperature. A fluorescence microscope (Olympus BX53, Tokyo, Japan) was taken to capture the PURPL fluorescence signal [34].

**Immunofluorescence**

Immunofluorescence confirmed the profiles of ZBTB7A, PI3K, AKT, and NF-kB in the tumor tissues. Prior to blocking with 5% BSA for an hour at room temperature, the sections were incubated along with primary antibodies Anti-ZBTB7A (ab240185), Anti-p-PI3K(ab182651), Anti-p-AKT (ab38449), and Anti-p-NF-kB (ab183559) for 15 hours at 4°C overnight. For TUNEL-labeled apoptotic cell detection, the blocked sections were incubated along with TUNEL testing solution (Beyotime, Shanghai, China) for 60 min at 37°C. The nucleus was then dyed employing DAPI (Beyotime, Shanghai, China) for 5 min at room temperature. A fluorescence microscope (Olympus BX53, Tokyo, Japan) was deployed to capture the fluorescence signals [35].

**The mouse xenograft tumor model**

Twenty male mice on a BALB/c background, 6–8 weeks of age and 18–22 g in weight, were ordered from the Animal Research Center of Shanghai Jiaotong University and reared under specific pathogen-free (SPF) housing, provided with sufficient food and water. Then the mice were kept as the hosts for gastric cancer transplantation at 25°C with the relative humidity of 60% to 70%. In this experiment, the animal procedures had received the green light from the Committee for Animal Protection of Xuhui hospital and were implemented in line with the Guide for the Care and Use of Laboratory Animals. The experiment had also received the imprimatur from the Medical Ethics Committee of Xuhui hospital of Zhongshan Hospital Affiliated to Fudan University (Approved number: XHH-2020-0122). Twenty nude mice were randomized to two groups, 10 mice for each. AGS cells transfected along with IncRNA PURPL overexpression plasmid and the vector...
plasmid were made into single-cell suspension of $1 \times 10^7$ cells per mL, which was inoculated into the mice on the right and posterior sides of the back so as to engineer a xenograft model of gastric cancer in the animals. The tumor volume was gauged and calculated adopting a vernier caliper on the 7th day, 14th day, 21st day, 28th day, and 35th day. Thirty-five days later, the mice were euthanized with the use of phenobarbital (50 mg/kg via i.p.), with their tumors isolated and weighed [36].

**Immunohistochemistry**

The tissues of the transplanted xenograft tumors in mice were routinely embedded in paraffin and sliced up (4 μm). The tissues were dewaxed using xylene, hydrated with gradient alcohol, and blocked with 3% H$_2$O$_2$ for 10 minutes to get the endogenous peroxidase inactivated. Microwave reparation (pH = 6.0, 15 minutes) was done with the use of 0.01 mol/L sodium citrate buffer. After being sealed with 5% bovine serum albumin (BSA) for 20 minutes, the sections were incubated along with the primary antibody Ki67 (concentration: 1:100) (ab15580) (purchased from Abcam, MA, USA) overnight at 4°C. The next day, the slices were incubated with the addition of the secondary antibody IgG at room temperature for 20 minutes. They were then colored with DAB (diaminobenzene) for imaging subsequent to PBS washing. Following redyeing with hematoxylin, the samples were dehydrated, made transparent, and sealed in preparation for microscopic examination.

**Statistical analysis**

The SPSS17.0 statistical software (SPSS Inc., Chicago, IL, USA) was exploited for statistical analysis, with the measurement statistics presented as ‘mean ± standard deviation (x ± s).’ $\chi^2$ was utilized to analyze the measurement data or percentages (%). ANOVA was taken for comparison among multiple groups, while an independent sample t-test was adopted to compare two groups. $P < 0.05$ was regarded statistically meaningful.

**Results**

In this study, we first evaluated the expression features of PURPL in GC tissues and cells. Next, the effects of PURPL in GC cell proliferation, migration, invasion, apoptosis, and growth were detected. The underlying mechanism of PURPL-miR-137-ZB7B7A axis was verified. Furthermore, PI3K/Akt /NF-κB pathway was intervened for confirming the role of this pathway regulated by URPL-miR-137-ZB7B7A axis.

**IncRNA PURPL presented a high expression in gastric cancer tissues and cells**

To grasp the expression features of PURPL in gastric cancer tissues, we gleaned the tumor tissues and normal adjacent tissues of 21 patients suffering from gastric cancer and determined PURPL expression in the tissues employing RT-PCR. PURPL expression was prominently enhanced in gastric cancer tissues as compared with normal tissues (Figure 1(a), $p < 0.05$). FISH indicated that PURPL was primarily situated at the cytoplasm of gastric cancer cells, while its level was lessened in the adjacent normal tissues (Figure 1(b)). RT-PCR confirmed the profile of PURPL in the normal gastric epithelial cell line GES-1 and gastric cancer cell lines AGS, GC9811-P, MKN-45, and HSC-39. In contrast with GES-1 cells, PURPL expression in AGS, GC9811-P, MKN-45, and HSC-39 cells was considerably uplifted (Figure 1(c), $p < 0.05$). Given the outcomes, we concluded that IncRNA PURPL presented a high profile in gastric cancer tissues and gastric cancer cells.

**IncRNA PURPL overexpression facilitated GC cell proliferation, migration, and invasion**

To disclose the influence of IncRNA PURPL on GC cell proliferation, migration, and apoptosis, we engineered a IncRNA PURPL overexpression model in AGS and MKN-45 cells. RT-PCR determined the profile of PURPL in the cell model. It was discovered that by contrast to the vec group, the PURPL group witnessed a substantial rise in the profile of PURPL (Figure 2(a), $p < 0.05$). Colony formation assay monitored cell proliferation, suggesting that compared to the vec group, there was a considerable uplift in cell proliferation in the PURPL group (Figure 2(b), $p < 0.05$). Transwell investigated cell migration and invasion, signaling a remarkable rise in cell migration and invasion in the PURPL group as opposed to the vec group (Figure 2(c), $p < 0.05$). Flow cytometry
examined cell apoptosis and uncovered that in contrast with the vec group, the PURPL group underwent a vigorous reduction in apoptosis (Figure 2(d), \( p < 0.05 \)). Western blot assessed apoptosis-concerned proteins, revealing that Bax and Caspase3 expressions were attenuated, while Bcl2's expression was elevated in the PURPL group vis-a-vis the vec group (Figure 2(e), \( p < 0.05 \)). These findings demonstrated that overexpression of IncRNA PURPL notably facilitated GC cells' proliferation, migration, and invasion and hampered their apoptosis.

**Overexpression of IncRNA PURPL boosted GC cell growth in vivo**

To dig deeper into the function of IncRNA PURPL overexpression in vivo, we inoculated the suspension of AGS cells with overexpression of IncRNA PURPL into the back of the mice on the right and posterior sides to establish a xenograft tumor model. The tumor volume was gauged and calculated employing a vernier caliper every seven days. It was disclosed that the tumor volume was evidently larger in the PURPL group than the vec group (Figure 3(a), \( p < 0.05 \)). Figure 3(b) displays the images of the mouse tumors. After weighing the mouse tumors, we unveiled that the tumor mass was remarkably enlarged in the PURPL group as compared with the vec group (Figure 3(c), \( p < 0.05 \)). The profile of the proliferation indicator Ki67 was confirmed via immunohistochemistry. As a result, the rate of positive Ki67 cells was much higher in the PURPL group compared to the vec group (Figure 3(d)). TUNEL signified a much lower level of apoptosis in the PURPL group as opposed to the vec group (Figure 3(e)). These discoveries unraveled that PURPL bolstered GC cell growth in vivo.

**IncRNA PURPL targeted miR-137 and enhanced ZBTB7A expression**

To unravel the correlation between IncRNA PURPL and miR-137, we consulted the bioinformatics database ENCORI (http://starbase.sysu.edu.cn/index.php) to figure out the targeted correlation between PURPL and miR-137. It was displayed that miR-137 was a valuable target of PURPL (Figure 4(a)). Dual luciferase activity assay pointed out that miR-137 mimics conspicuously abated the luciferase activity of AGS cells transfected along with PURPL-WT but exerted little influence on that of AGS cells transfected along with PURPL-MT (Figure 4(b), \( p < 0.05 \)). RT-PCR ascertained miR-137 and ZBTB7A mRNA expressions in the AGS and MKN-45 cell models with PURPL overexpression and the xenograft tumor model. It came to light that in contrast with the vec group, the PURPL group experienced a notable reduction in miR-137 profile and a remarkable rise in ZBTB7A's expression (Figure 4(c-g), \( P < 0.05 \)). These data confirmed that PURPL bolstered ZBTB7A's expression via miR-137 inhibition.

**IncRNA PURPL influenced GC development via miR-137/ZBTB7A axis regulation**

To delve into the function of IncRNA PURPL in the miR-137/ZBTB7A axis in the field of gastric cancer, we transfected miR-137 mimics (miR-137) or si-ZBTB7A into the AGS cell model with overexpression of PURPL. RT-PCR confirmed the profiles of PURPL,
miR-137, and ZBTB7A in the cells from each group. There was a decline in ZBTB7A and PURPL expressions in the PURPL+miR-137 and PURPLE+si-ZBTB7A groups as opposed to the PURPL1 group (Figure 5(a-c), $P < 0.05$). Colony formation assay monitored cell proliferation in each group, indicating
a distinct reduction in proliferation in the PURPL +miR-137 and PURPL+si-ZBTB7A groups vis-a-vis the PURPL1 group (Figure 5(d), p < 0.05). Transwell tracked cell migration and invasion, unveiling that these activities were considerably augmented in the PURPL group against the VEC group. In contrast with the PURPL1 group, the PURPL+miR-137 and PURPL +si-ZBTB7A groups underwent a remarkable decline in migration and invasion (Figure 5(e), p < 0.05). Flow cytometry reflected a notable decline in the apoptosis rate in the PURPL group as compared with the vec group. In contrast with the PURPL1 group, apoptosis was prominently stepped up in the PURPL+miR-137 group and PURPL+si-ZBTB7A groups (Figure 5(f), p < 0.05). Western blot analyzed apoptosis-concerned proteins, suggesting that by contrast to the PURPL group, the PURPL+miR-137 and PURPL+si-ZBTB7A groups experienced a rise in Bax and Caspase3 expressions and a reduction in Bcl2’s expression (Figure 5(g), p < 0.05). These findings demonstrated that PURPL overexpression suppressed miR-137 expression and enhanced ZBTB7A expression to exert a promoting function in gastric cancer cells.

IncRNA PURPL initiated the ZBTB7A/PI3K/Akt / NF-kB pathway ex vivo and in vivo

To better understand the regulatory correlation between PURPL and the PI3K/AKT/NF-kB pathway, we implemented Western blot and immunofluorescence to reveal the profile of the PI3K/AKT/NF-kB axis in the nude mouse tumor tissues. It transpired that PI3K, AKT, and NF-kB phosphorylation were remarkably expanded in the PURPL group (compared...
to the vec group) (Figure 6(a-b), \( P < 0.05 \)). Western blot determined PI3K/AKT/NF-κB expression in the AGS cell model with PURPL overexpression, which was transfected along with miR-137 mimics (miR-137) or si-ZBTB7A. In contrast with the vec group, PI3K/AKT/NF-κB phosphorylation was dramatically enhanced in the PURPL group (Figure 6(a-b), \( P < 0.05 \)). PI3K/AKT/NF-κB activation was markedly dampened in the PURPL+miR-137 and PURPL+si-ZBTB7A groups as compared with the PURPL group (Figure 6(c), \( P < 0.05 \)). All the discoveries signified that PURPL elevated ZBTB7A’s expression and initiated the PI3K/AKT/NF-κB pathway, hence bringing into full play its substantial cancer-promoting function.

**Inhibition of PI3K and NF-κB weakened the cancer-promoting function mediated by IncRNA PURPL**

To further corroborate the impact of PI3K/AKT/NF-κB axis on the carcinogenic function of PURPL, the PI3K inhibitor LY294002 (10 μM, Article number: HY-10108) and the NF-κB inhibitor JSH-23 (30 μM, article number: HY-13982) were administered to the AGS cell model with overexpression of PURPL. Colony formation assay examined cell proliferation. As a result, cell proliferation was evidently stepped up in the PURPL group vis-à-vis the vec group. In contrast with the PURPL group, the PURPL+LY294002 and PURPL+JSH-23 groups experienced a vast reduction in proliferation (Figure 7(a), \( p < 0.05 \)). Migration and invasion were considerably augmented in the PURPL group as opposed to the vec group. In contrast with the PURPL group, GC cell migration and invasion were distinctly attenuated in the PURPL+LY294002 and PURPL+JSH-23 groups (Figure 7(b), \( p < 0.05 \)). Flow cytometry tracked cell apoptosis, revealing that in contrast with the PURPL group, the PURPL+LY294002 and PURPL+JSH-23 groups witnessed a notable rise in apoptosis (Figure 7(c), \( p < 0.05 \)). Western blot evaluated apoptosis-concerned proteins and displayed that there was a rise in Bax and Caspase3 expressions and a decline in Bcl2’s expression in the PURPL+LY294002 and PURPL+JSH-23 groups as compared with the PURPL group (Figure 7(d), \( p < 0.05 \)). Western blot investigated the protein profile of the PI3K/AKT/NF-κB pathway. By contrast to the PURPL group, PI3K, AKT, and NF-κB phosphorylation were markedly abated in the PURPL+LY294002 group and the PURPL+JSH-23 group (Figure 7(e), \( p < 0.05 \)). RT-PCR unveiled that ZBTB7A knockdown or PI3K or NF-κB inhibition culminated in down-regulated IncRNA PURPL and up-regulated miR-137 (Figure 8(a-f)). Thus, IncRNA PURPL mediated GC cell proliferation, migration, and invasion via the miR-137-ZBTB7A-PI3K/AKT/NF-Kb pathway.
**Figure 5.** IncRNA PURPL influenced GC progression via miR-137/ZBTB7A axis regulation. miR-137 mimics (miR-137) or si-ZBTB7A was transfected into AGS cells with PURPL overexpression. A-C. RT-PCR confirmed the profiles of PURPL, miR-137, and ZBTB7A in AGS cells. D. Colony formation assay examined proliferation. E. Transwell monitored cell migration and invasion. F. Flow cytometry determined the apoptosis rate of AGS cells. G. The profiles of apoptosis-concerned proteins Bax, Bcl2, and Caspase3 were figured out through Western blot. **P < 0.01, ***P < 0.001 (vs. the vec group), ##P < 0.01, ###P < 0.001 (vs. the PURPL group). N = 3.
The figure shows that IncRNA PURPL activated the ZBTB7A/PI3K/AKT/NF-κB pathway. Western blot determined the profile of the PI3K/AKT/NF-κB pathway in the nude mouse tumor tissues. B. Immunofluorescence assessed PI3K/AKT/NF-κB in the tumor tissues. C. Western blot evaluated the PI3K/AKT/NF-κB pathway in AGS cells transfected along with PURPL overexpression, miR-137 mimics, or si-ZBTB7A. ***P < 0.001 (vs. the vec group), # P < 0.05 (vs. the PURPL group). N = 3.

**Discussion**

Gastric cancer, a malignant tumor, is accompanied by extremely high clinical occurrence and mortality rates and particularly poor prognosis [37]. With constant exploration of genetic technologies, it has been disclosed that GC occurrence and development are correlated with gene mutations, chromosomal aberrations, and epigenetic alterations [38,39]. Here, we discovered that GC development bore a relation to the aberrant profile of IncRNA PURPL. Highly-expressed
PURPL hampered miR-137, bolstered ZBTB7A, initiated the PI3K/AKT/NF-κB pathway, and elicited GC cell proliferation, migration, and apoptosis inhibition (Figure 9).

lncRNA dysregulation has been demonstrated to have something to do with GC occurrence and development by a multitude of studies [40]. The profile of lncRNA maternally expressed 3 (MEG3) is much...
lower in GC tissues than in normal adjacent tissues, and the P53 signaling pathway initiated by IncRNA MEG3 overexpression curbs GC proliferation and metastasis [41]. Overexpression of IncRNA PVT1 activates the STAT3/VEGFA pathway, sparks the angiogenesis in tumor cells, and vigorously boosts GC progression in vitro and in vivo [42]. Impressively, emerging IncRNAs have been found with clinical application values in tumors. For example, IncRNA scores predict the overall survival of tumor patients and they have the potential in immunotherapy prediction [43]. Another study revealed that IncRNA TINCR rs2288947 A > G con predict increased bladder cancer risk and rs8113645 C > T is associated with decreased susceptibility [44]. However, there seems to be a long way to go for IncRNA to be used in clinical tumor treatment. One of the main reasons is the diversity of Incrna targets and the complexity of functions.

Different IncRNAs embody varied effects in gastric cancer due to diverse IncRNA molecules leading to diverse downstream target genes. IncRNA PURPL, a proto-oncogene, exerts an essential cancer-promoting function in colorectal cancer and hepatocellular carcinoma [13,45]. PURPL expression is evidently leveled up in GC tissues as compared with normal adjacent tissues, the profile level of PURPL positively correlates with the tumor size and pathological grade of the cancer, and it functions as an underlying molecular marker for GC diagnosis [46]. PURPL overexpression suffocates p53 activation, elevates the profile of Bcl2, elicits EMT, and facilitates GC development. Curcumin analog DA 0324 can lower the profile of PURPL and impede malignant GC progression [47]. The carcinogenic properties of PURPL in gastric cancer have been verified. The study, aligned to earlier works, also revealed the high profile of IncRNA PURPL in GC tissues and cells. Overexpression of PURPL stepped up GC cells’ proliferation, migration, and invasion, curbed their apoptosis, and prominently triggered GC cell growth and proliferation in vivo and ex vivo.

IncRNAs can influence GC cell proliferation, growth, migration, invasion, and apoptosis via miRNA modulation [48]. miR-137, a member of the miRNA family, has been confirmed to function as a tumor suppressor and present an abnormal expression in multiple cancers [49]. The profile of miR-137 is notably lower in GC tumor tissues than normal adjacent tissues. miR-137 overexpression

---

Figure 8. Down-regulation of the ZBTB7A/Pi3K/AKT/NF-κB pathway mitigated PURPL’s level. si-ZBTB7A was transfected into AGS cells. A-B. RT-PCR examined PURPL and miR-137. C-F. LY294002 (10 μM) and JSH-23 (30 μM) were given to AGS cells for Pi3K or NF-κB inhibition. RT-PCR assessed PURPL and miR-137. ***P < 0.001. N = 3.
restrains KLF 12 and Myo1c expressions, thus impeding the proliferation, migration, and inheritance of GC cells BGC-823 and SGC-7901 and culminating in apoptosis [50]. miR-137 is targeted by IncRNA NCK1-AS1. Low NCK1-AS1 expression augments the profile of miR-137, reduces that of NUP 43, and represses GC cell proliferation, migration, and invasion [51]. The inhibitory impact of miR-137 on GC has been substantiated by the above findings. Here, we discovered that IncRNA PURPL targeted miR-137 and stymied its profile, therefore initiating the PI3K/AKT/NF-κB pathway and eliciting malignant GC development. The anti-tumor function of miR-137 in gastric cancer is in lockstep with what the previous works have found.

As an essential transcriptional inhibitor, ZBTB7A presents an abnormal expression in non-small cell lung cancer, breast cancer, and other cancers [52,53]. For instance, considering that ZBTB7A can exert an oncogenic function in colorectal cancer patients, it can be taken as an underlying biomarker and therapeutic target for colorectal cancer [54]. Moreover, its high profile is linked to a poor prognosis in GC patients. miR-100 targets and suppresses ZBTB7A’s expression, thus cramping tumor cell migration and invasion [55]. Nevertheless, there is a different opinion that overexpression of ZBTB7A contributes to GC cells’ cycle arrest, curbs their migration, and steps up their apoptosis, and it displays a remarkable tumor-suppressing function in the context of GC [56]. ZBTB7A produces distinct effects in the cancer. That’s because it exerts an impact on GC cells via different mechanisms. PI3K/AKT/NF-κB, also a typical signaling pathway in tumors, is modulated by diverse molecules like IncRNAs, miRNAs, and proteins. It exhibits an aberrant expression in a multitude of tumor cells and correlates with cancer cell proliferation, migration, and invasion [57]. IncRNA DANCR can drive up the transcriptional level, initiate the PI3K/AKT/NF-κB pathway, mediate glioma cells’ resistance to cisplatin, and hinder cell apoptosis via combining the profiles of umpteen miRNAs like miR-33a-5p, miR-33b-5p, miR-1-3p, miR-206, and miR-613 in

---

**Figure 9.** Schematic diagram of PURPL-miR-137-ZBTB7A/PI3K/AKT/NF-κB axis in GC development.
a competitive manner [58]. Celastrol drives down miR-21’s expression, and low miR-21 expression curbs the activation of the pathway, hence restraining GC progression [59]. Here, we uncovered that ZBTB7A modulated tumor development through its influence on various typical signaling pathways. It vigorously initiated PI3K/AKT/NF-κB phosphorylation in GC, exhibiting an outstanding carcinogenic function. As displayed by our experiments, lncRNA PURPL targeted and hampered miR-137, elevated the profile of ZBTB7A, activated the PI3K/AKT/NF-κB pathway, and stepped up GC occurrence and development. Inhibition of PI3K or NF-κB could conspicuously mitigate lncRNA PURPL-mediated cancer-promoting effects and lncRNA PURPL expression.

However, several limitations need to be addressed in our future studies: 1) The specific mechanism of NF-κB on lncRNA PURPL expression should be confirmed; 2) The function of lncRNA PURPL-miR-137-ZBTB7A in GC progression should be verified in animal models; 3) More clinical samples need to be collected for evaluating the significance of lncRNA PURPL-miR-137-ZBTB7A on GC diagnosis and prognostic evaluation.

Conclusion

Taken together, our work has verified that the lncRNA PURPL-miR-137-ZBTB7A-PI3K-AKT-NF-κB feedback loop can vigorously boost the malignant progression of gastric cancer (Figure 9). lncRNA PURPL targets miR-137, drives up ZBTB7A expression, and initiates PI3K-AKT-NF-κB pathway phosphorylation. PI3K or NF-κB inhibition considerably weakens the cancer-promoting function mediated by lncRNA PURPL. Our efforts have discovered a novel feedback loop, which hints that lncRNA PURPL may be an efficacious target for GC treatment.

List of abbreviations

BSA: Bovine serum albumin; DAB: Diaminobenzene; EMT: Epithelial-mesenchymal transformation; FBS: Fetal bovine serum; FISH: Fluorescence in situ hybridization; GC: Gastric cancer; lncRNA: long non-coding RNA; MEG3: maternally expressed 3; miRNA: microRNA; NC: negative control; NF-κB: nuclear factor-kappaB; NS: no significance; PI: Propidium iodide; PURPL: p53 upregulated regulator of p53 levels; PVDF: Polyvinylidene fluoride; RT-qPCR: Real-time quantitative polymerase chain reaction; si-NC: small interfere RNA negative control; SPF: Specified pathogen-free; WB: Western blot; ZBTB7A: zinc finger and BTB domain containing 7A.

Disclosure statement
No potential conflict of interest was reported by the author(s).

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethical approval
Our study was approved by the Ethics Committee in The Central Hospital of Xuhui District, Xuhui hospital, Zhongshan Hospital Affiliated to Fudan University.

Data Availability Statement
The data sets used and analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
All authors participated in the design, interpretation of the studies and analysis of the data and review of the manuscript; ZF guaranteed the integrity of entire study, ZHC designed the conception of study, JH made the definition of intellectual content, NT researched relevant literature, FHL conducted the clinical studies, SG conducted the experimental studies, JH did the data acquisition and statistical analysis, ZHC wrote the manuscript, ZF reviewed the manuscript.

References

[1] Jemal A, Center MM, DeSantis C, et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893–1907. Epub 2010 Jul 20. PMID: 20647400.
[2] Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer. Lancet. 2020 Aug 29;396(10251):635–648. PMID: 32861308.
[3] Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):700–713. Epub 2014 Mar 11. PMID: 24618998; PMCID: PMC4019373.
[4] Cunningham SC, Kamangar F, Kim MP, et al. Survival after gastric adenocarcinoma resection: eighteen-year
experience at a single institution. J Gastrointest Surg. 2005May-Jun;9(5):718–725. PMID: 15862270.

[5] Diglilia A. Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol. 2016Feb28;22(8):2403–2414. i8.2403. PMID: 26937129; PMCID: PMC4768187.

[6] Song Z, Wu Y, Yang J, et al. Progress in the treatment of advanced gastric cancer. Tumor Biol. 2017Jul;39(7):101042317714626. PMID: 28671042.

[7] Jathar S, Kumar V, Srivastava J, et al. Technological Developments in IncRNA Biology. Adv Exp Med Biol. 2017;1008:283–323. PMID: 28815544.

[8] Liu K, Zhao D, Wang D. LINC00528 regulates myocardial infarction by targeting the miR-143-3p/COX-2 axis. Bioengineered. 2020Dec;11(1):11–18. PMID: 31833800; PMCID: PMC6961595.

[9] Ding J, Cao J, Chen Z, et al. The role of long intergenic noncoding RNA 00511 in malignant tumors: a meta-analysis, database validation and review. Bioengineered. 2020 Dec;11(1):812–823.

[10] Thin KZ, Liu X, Feng X, et al. LncRNA-DANCR: a valuable cancer-related long non-coding RNA for human cancers. Pathol Res Pract. 2018 Jun;214(6):801–805. Epub 2018 Apr 24. PMID: 29728310.

[11] Deng W, Zhang Y, Cai J, et al. LncRNA-ANRIL promotes gastric cancer progression by enhancing NF-kB signaling. Exp Biol Med (Maywood). 2019 Sep;244(12):953–959. Epub 2019 Jun 26. PMID: 31242038; PMCID: PMC6879767.

[12] Li H, Wang Y. Long Noncoding RNA (IncRNA) MIR22HG Suppresses Gastric Cancer Progression through Attenuating NOTCH2 Signaling. Med Sci Monit. 2019Jan23;25:656–665.PMID: 30670679; PMCID: PMC6352764.

[13] Fu X, Wang Y, Wu G, et al. Long noncoding RNA PURPL promotes cell proliferation in liver cancer by regulating p53. Mol Med Rep. 2019Jun;19(6):4998–5006. Epub 2019 Apr 12. PMID: 31059022.

[14] Zhang R, He T, Shi H, et al. Disregulations of PURPL and MiR-338-3p Could Serve As Prognosis Biomarkers for Epithelial Ovarian Cancer. J Cancer. 2021Jul25;12(18):5674–5680. PMID: 34405027; PMCID: PMC8364645.

[15] Chen L, Heikkinen L, Wang C, et al. Trends in the development of miRNA bioinformatics tools. Brief Bioinform. 2019Sep27;20(5):1836–1852. PMID: 29982332; PMCID: PMC7414524.

[16] Correia de Sousa M, Gjorgjieva M, Dolicka D, et al. Deciphering miRNAs’ Action through miRNA Editing. Int J Mol Sci. 2019Dec11;20(24):6249. PMID: 31835747; PMCID: PMC6949109.

[17] Shin YV. MiRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol. 2014Aug14;20(30):10432–10439. PMID: 25132759; PMCID: PMC4130850.

[18] Mu L, Yang F, Guo D, et al. Overexpression of secretory clusterin (sCLU) induces chemotherapy resistance in human gastric cancer cells by targeting miR-195-5p. Bioengineered. 2020 Dec;11(1):472–483. PMID: 32250192; PMCID: PMC7161562.

[19] Pei Y, Tang Z, Cai M, et al. MicroRNA miR-425 promotes tumor progression by inhibiting Dickkopf-related protein-3 in gastric cancer. Bioengineered. 2021 Dec;12(1):2045–2054. PMID: 34124998.

[20] He X, Zou K. MiRNA-96-5p contributed to the proliferation of gastric cancer cells by targeting FOXO3. J Biochem. 2020Jan1;167(1):101–108. PMID: 31598681.

[21] Wang C, Huang Y, Zhang J, et al. MiRNA-339-5p suppresses the malignant development of gastric cancer via targeting ALKBH1. Exp Mol Pathol. 2020 Aug; 115: 104449.Epub 2020 May 5. PMID: 32380054.

[22] Duan J, Lu G, Li Y, et al. Tao H. miR-137 functions as a tumor suppressor gene in pituitary adenoma by targeting AKT2. Int J Clin Exp Pathol. 2019 May;12(5):1557–1564. PMID: 31933973; PMCID: PMC6947140.

[23] Ding X, Zhang J, Feng Z, et al. MiR-137-3p Inhibits Colorectal Cancer Cell Migration by Regulating a KDM1A-Dependent Epithelial-Mesenchymal Transition. Dig Dis Sci. 2020 Aug;66(7):2272–2282. Epub ahead of print. PMID: 32749639.

[24] Zheng X, Wang X, Zheng L, et al. Construction and Analysis of the Tumor-Specific mRNA-miRNA-lncRNA Network in Gastric Cancer. Front Pharmacol. 2020 Jul;11:1112.PMID: 32848739; PMCID: PMC7396639.

[25] Wang J, Ding Y, Wu Y, et al. Identification of the complex regulatory relationships related to gastric cancer from lncRNA-miRNA-mRNA network. J Cell Biochem. 2020 Jan;121(1):876–887. Epub 2019 Aug 26. PMID: 31452262.

[26] Chen Z, Wu J, Huang W, et al. Long Non-Coding RNA RP11-789C1.1 Suppresses Epithelial to Mesenchymal Transition in Gastric Cancer Through the RP11-789C1.1/MiR-5003/E-Cadherin Axis. Cell Physiol Biochem. 2018;47(6):2432–2444. Epub 2018 Jul 10. PMID: 29991048.

[27] Gupta S, Singh AK, Prajapati KS, et al. Emerging role of ZBTB7A as an oncogenic driver and transcriptional repressor. Cancer Lett. 2020 Jul 28;483:22–34. Epub 2020 Apr 26. PMID: 32348807.

[28] Wang S, Li P, Jiang G, et al. Long non-coding RNA LOC285194 inhibits proliferation and migration but promoted apoptosis in vascular smooth muscle cells via targeting miR-211/PUMA and TGF-β1/S100A4 signal. Bioengineered. 2020 Dec;11(1):718–728. PMID: 32619136; PMCID: PMC8291892.

[29] Fu Y, Hu X, Gao Y, et al. LncRNA ROR/miR-145-5p axis modulates the osteoblasts proliferation and apoptosis in osteoporosis. Bioengineered. 2021 Dec;12(1):7714–7723. PMID: 34617877.

[30] Xu M, Chen X, Lin K, et al. The long noncoding RNA SNHG1 regulates colorectal cancer cell growth through
interactions with EZH2 and miR-154-5p. Mol Cancer. 2018 Sep;28(17):141. PMID: 30266084; PMCID: PMC6162892.

[31] Wang X, Li T. Ropivacaine inhibits the proliferation and migration of colorectal cancer cells through ITGB1. Bioengineered. 2021 Dec;12(1):44–53. PMID: 33345684.

[32] Duan L, Tao J, Yang X, et al. HVEM/HIF-1a promoted proliferation and inhibited apoptosis of ovarian cancer cells under hypoxic microenvironment conditions. J Ovarian Res. 2020 Apr;20(1):40.

[33] Li JH, Liu S, Zhou H, et al. starBase v2.0: decoding miRNA-ceRNA, miRNA-nceRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014 Jan;42(Database issue):D92–7. Epub 2013 Dec 1. PMID: 24297251; PMCID:PMC3964941.

[34] Hu YP, Jin YP, Wu X, et al. LncRNA-HGBC stabilized by HuR promotes gallbladder cancer progression by regulating miR-502-3p/SET/AKT axis. Mol Cancer. 2019 Nov;21(18):167. Erratum in: Mol Cancer. 2021 Aug 28;20(1):110. PMID: 31752906; PMCID:PMC6868746.

[35] Guan S, Jin T, Han S, et al. Dihydroartemisinin alleviates morphine-induced neuroinflammation in BV-2 cells. Biomech Eng. 2021 Dec;12(2):9401–9410. PMID: 34854364.

[36] Jie Y, Ye L, Chen H, et al. ELFN1–AS1 accelerates cell proliferation, invasion and migration via regulating miR-497-3p/CLDN4 axis in ovarian cancer. Bioengineered. 2020 Dec;11(1):872–882. PMID: 32779991; PMCID: PMC8291874.

[37] Den Hoed CM, Kuipers EJ. Gastric Cancer: how Can We Reduce the Incidence of this Disease? Curr Gastroenterol Rep. 2016 Jul;18(7):34. PMID: 27184043; PMCID:PMC4868864.

[38] Chia NY, Tan P. Molecular classification of gastric cancer. Ann Oncol. 2016 May;27(5):763–769. Epub 2016 Feb 9. PMID: 26861606.

[39] Vega-Benedetti AF, Loi E, Moi L, et al. Clustered protocadherins methylation alterations in cancer. Clin Epigenetics. 2019 Jul;9(11):100. PMID: 31288858; PMCID:PMC6617643.

[40] Ma B, Li Y, Ren Y. Identification of a 6-lncRNA prognostic signature based on microarray re-annotation in gastric cancer. Cancer Med. 2020 Jan;9(1):335–349. Epub 2019 Nov 19. PMID: 31743579; PMCID:PMC6943089.

[41] Wei GH, Wang X. LncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. Eur Rev Med Pharmacol Sci. 2017 Oct;21(17):3850–3856. PMID: 28975980.

[42] Zhao J, Du P, Cui P, et al. LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer. Oncogene. 2018 Jul;37(30):4094–4109. Epub 2018 Apr 30. PMID: 29706652.

[43] Yu Y, Zhang W, Li A, et al. Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer. JAMA Network Open. 2020 Apr 1;3(4):e202149. PMID: 32259264; PMCID:PMC7139278.

[44] Xu C, Liu M, Jia D, et al. LncRNA TINCR SNPs and Expression Levels Are Associated with Bladder Cancer Susceptibility. Genet Test Mol Biomarkers. 2021 Jan;25(1):31–41. Epub 2020 Dec 28. PMID: 33372851.

[45] Li XY, Subramanian M, Jones MF, et al. Long Noncoding RNA PURPL Suppresses Basal p53 Levels and Promotes Tumorigenicity in Colorectal Cancer. Cell Rep. 2017 Sep;5;20(10):2408–2423. PMID: 28877474; PMCID:PMC5777516.

[46] Moridi H, Karimi J, Tavilani H, et al. Overexpression of PURPL and downregulation of NONHSAT062994 as potential biomarkers in gastric cancer. Life Sci. 2019 Nov 15;237:116904. Epub 2019 Oct 10. PMID: 31606380.

[47] Xu F, Ji Z, He L, et al. Downregulation of LINC01021 by curcumin analog Da0324 inhibits gastric cancer progression through activation of P53. Am J Transl Res. 2020 Jul 15;12(7):3429–3444. PMID: 32774710; PMCID:PMC7407729.

[48] Hao NB, He YF, Li XQ, et al. The role of miRNA and lncRNA in gastric cancer. Oncotarget. 2017 Jul 12;8(46):81572–81582. PMID: 29113415; PMCID:PMC5655310.

[49] Mahmoudi E, Cairns MJ. MiR-137: an important player in neural development and neoplastic transformation. Mol Psychiatry. 2017 Jan;22(1):44–55. Epub 2016 Sep 13. PMID: 27620842; PMCID:PMC5414082.

[50] Du Y, Chen Y, Wang F, et al. miR-137 plays tumor suppressor roles in gastric cancer cell lines by targeting KLF12 and MYO1C. Tumour Biol. 2016 Oct;37(10):13557–13569. Epub 2016 Jul 28. PMID: 27468717.

[51] Li W, Duan J, Shi W, et al. Long Non-Coding RNA NCK1–AS1 Serves as Oncogenic Role in Gastric Cancer by Regulating miR-137/NUP43 Axis. Onco Targets Ther. 2020 Oct;13:9929–9939.PMID: 33116577; PMCID:PMC7547806.

[52] Zhijun Z, Jingkang J. MicroRNA-520e suppresses non-small-cell lung cancer cell growth by targeting the Zbtb7a-mediated Wnt signaling pathway. Biochem Biophys Res Commun. 2017 Apr 22;486(1):49–56. Epub 2017 Feb 27. PMID: 28242196.

[53] Mao A, Chen M, Qin Q, et al. ZBTB7A promotes migration, invasion, and metastasis of human breast cancer cells through NF-κB-induced epithelial-mesenchymal transition in vitro and in vivo. J Biochem. 2019 Dec;166(6):485–493. PMID: 31385585.
[54] Wang L, Zhang MX, Zhang MF, et al. ZBTB7A functioned as an oncogene in colorectal cancer. BMC Gastroenterol. 2020 Nov;9(1):370. PMID: 33167891; PMCID: PMC7650168.

[55] Shi DB, Wang YW, Xing AY, et al. C/EBPα-induced miR-100 expression suppresses tumor metastasis and growth by targeting ZBTB7A in gastric cancer. Cancer Lett. 2015 Dec 28;369(2):376–385. Epub 2015 Sep 25. PMID: 26404754.

[56] Sun G, Peng B, Xie Q, et al. Upregulation of ZBTB7A exhibits a tumor-suppressive role in gastric cancer cells. Mol Med Rep. 2018 Feb;17(2):2635–2641. Epub 2017 Nov 20. PMID: 29207095.

[57] Chen H, Zhou L, Wu X, et al. The PI3K/AKT pathway in the pathogenesis of prostate cancer. Front Biosci (Landmark Ed). 2016 Jun;21(5):1084–1091. PMID: 27100493.

[58] Ma Y, Zhou G, Li M, et al. Long noncoding RNA DANCR mediates cisplatin resistance in glioma cells via activating AXL/PI3K/AKT/NF-κB signaling pathway. Neurochem Int. 2018 Sep; 118: 233–241. Epub 2018 Mar 21. PMID: 29572052.

[59] Sha M, Ye J, Zhang LX, et al. Celastrol induces apoptosis of gastric cancer cells by miR-21 inhibiting PI3K/Akt-NF-κB signaling pathway. Pharmacology. 2014;93(1–2):39–46. Epub 2014 Jan 15. PMID: 24434352.